Stromal cell-derived factor 1 (SDF-1), also known as C-X-C motif chemokine 12 (CXCL12), is a chemokine protein that can activate STAT3 and Akt signaling ways and protect the heart from ischemia-reperfusion injury. As a secreted 89-amino acid protein, SDF-1/CXCL12 binds to chemokine receptor type 4 (CXCR4), a seven-pass G-protein-coupled membrane receptor.
SDF-1 is generated in two forms: SDF-1α/CXCL12a and SDF-1β/CXCL12b. Chemokines are labelled by the presence of four conserved cysteines forming two disulfide bonds. The former one, SDF-1/CXCL12 protein, belong to the CXC class of chemokines, whose original pair of cysteines are separated by one intervening amino acid. Furthermore, the first eight residues at the N-terminal end of SDF-1/CXCL12 provide receptor binding sites, but only Lys-1 and Pro-2 are directly involved in receptor activation.
Potential Applications of SDF-1
SDF-1/CXCL12 recruits cardiac and bone marrow-derived stem cells and appears to stimulate cardiac angiogenesis and vasculogenesis in a paracrine way. Recombinant SDF-1/CXCL12 or recombinant vectors (e.g. plasmids) encoding SDF-1/CXCL12 have been developed for the treatment of peripheral arterial disease (PAD) in preclinical and clinical trials.
A phase I clinical trial (NCT01082094) showed no significant safety concerns related to gene transfer of a DNA plasmid encoding human SDF-1.
Yaohai Bio-Pharma Offers One-Stop CDMO Solution for SDF-1
SDF-1 Pipelines
|
Generic Name
|
Brand Name/
Alternative Name
|
Indications
|
Manufacturer
|
Latest Stage
|
|
JVS-100
|
GP51801
|
Peripheral arterial disease, Heart failure, Peripheral ischemia, Perioperative ischemia, Surgical wounds, Fecal incontinence
|
Nanjing Jiqun Biotechnology, Juventas Therapeutics.
|
Phase II
|
|
4P-021
|
Pending update
|
novel coronavirus infection
|
4P-Pharma
|
Phase II
|
|
AD-214
|
Pending update
|
Gastroesophageal Reflux, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
|
AdAlta Ltd., Addpharma.
|
Phase I
|
|
CK-0804
|
Pending update
|
primary myelofibrosis
|
Cellenkos.
|
Phase I
|
|
MB-1707
|
Pending update
|
Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumors
|
Mainline Biosciences.
|
Phase I
|
|
Auto immune disease therapy
|
Pending update
|
autoimmune disease
|
Ermium Therapeutics SAS
|
Pre-clinical
|
|
GP 01CR11
|
Pending update
|
tumor
|
GPCR Co., Ltd.
|
Pre-clinical
|
|
GP-01CR21
|
Pending update
|
tumor
|
GPCR Co., Ltd.
|
Pre-clinical
|
SL
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
